| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Alpha-Tocopherol phosphate's biological activity is primarily attributed to its role as a potent antioxidant. As a derivative of vitamin E, it scavenges free radicals and protects cells from oxidative damage. It also acts as a vascular endothelial growth factor (VEGF) inducer. The phosphate group may enhance its water solubility and bioavailability compared to other forms of vitamin E. The compound's mechanism of action involves its ability to donate a hydrogen atom to free radicals, thereby neutralizing them and preventing lipid peroxidation.
|
|---|---|
| ln Vitro |
In vitro, Alpha-Tocopherol phosphate has been studied for its antioxidant and cell-protective effects. Its activity is typically measured using assays that assess its ability to scavenge free radicals, such as the DPPH or ABTS assays. It has been shown to protect cells from oxidative stress-induced damage. The compound's ability to induce VEGF expression has also been demonstrated in cell-based assays. However, specific in vitro data, such as IC50 or EC50 values, are not detailed in standard product descriptions.
|
| ln Vivo |
In vivo, Alpha-Tocopherol phosphate is used as a source of vitamin E in nutritional and biomedical research. Vitamin E is an essential nutrient with antioxidant properties that protect cells from oxidative damage. The compound's role as a VEGF inducer suggests potential applications in wound healing and angiogenesis. However, specific in vivo protocols and results are not detailed in standard product descriptions. Alpha-Tocopherol phosphate is a research compound used to study vitamin E biology.
|
| Enzyme Assay |
In vitro assays for Alpha-Tocopherol phosphate measure its antioxidant activity. The compound's ability to scavenge free radicals is assessed using assays such as DPPH (2,2-diphenyl-1-picrylhydrazyl) or ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)). The compound's ability to inhibit lipid peroxidation can be measured using assays such as the thiobarbituric acid reactive substances (TBARS) assay. These assays confirm the compound's antioxidant activity.
|
| Cell Assay |
In vitro cell-based assays for Alpha-Tocopherol phosphate are used to study its cytoprotective effects. Cells are treated with the compound and then exposed to oxidative stress inducers, such as hydrogen peroxide. Cell viability is assessed using assays such as MTT or LDH release. The compound's ability to protect cells from oxidative damage is measured. These assays confirm the compound's antioxidant and cytoprotective activity.
|
| Animal Protocol |
In vivo animal experiments for Alpha-Tocopherol phosphate are conducted in models of oxidative stress and vitamin E deficiency. In a typical study, animals are fed a vitamin E-deficient diet and then supplemented with Alpha-Tocopherol phosphate. The compound's ability to restore vitamin E levels and protect against oxidative damage is assessed. These studies provide evidence for the in vivo efficacy of Alpha-Tocopherol phosphate as a source of vitamin E.
|
| ADME/Pharmacokinetics |
Alpha-Tocopherol phosphate has a molecular weight of 510.69 g/mol and a molecular formula of C29H51O5P. It has a CAS number of 38976-17-9. It is a solid compound with a white to khaki appearance. For storage, it is recommended to keep the powder at -20°C. Detailed pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME) have been characterized. As a phosphate ester, it may have enhanced water solubility and bioavailability.
|
| Toxicity/Toxicokinetics |
Alpha-Tocopherol phosphate is generally recognized as safe (GRAS) as a source of vitamin E. It is a naturally occurring compound and is considered to have low toxicity. As with all chemicals, standard laboratory safety precautions should be followed when handling Alpha-Tocopherol phosphate. Its use is limited to research applications and it is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
Alpha-Tocopherol phosphate is a research compound and is not approved for any clinical or therapeutic use. It is a phosphate ester derivative of α-tocopherol, the most active form of vitamin E. It is a compound demonstrating the highest vitamin E activity. Alpha-Tocopherol phosphate is used to study the biological activities of vitamin E, including its antioxidant properties and its role as a vascular endothelial growth factor (VEGF) inducer. It is a valuable research tool for studying vitamin E biology and oxidative stress.
|
| Molecular Formula |
C29H51O5P
|
|---|---|
| Molecular Weight |
510.68604
|
| Exact Mass |
510.347
|
| CAS # |
38976-17-9
|
| PubChem CID |
94493
|
| Appearance |
White to khaki solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
615.3±65.0 °C at 760 mmHg
|
| Flash Point |
325.9±34.3 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.503
|
| LogP |
10.78
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
35
|
| Complexity |
664
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC1=C(C(=C(C2=C1O[C@](CC2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)OP(=O)(O)O)C
|
| InChi Key |
JUIUXBHZFNHITF-IEOSBIPESA-N
|
| InChi Code |
InChI=1S/C29H51O5P/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(34-35(30,31)32)23(5)24(6)28(26)33-29/h20-22H,9-19H2,1-8H3,(H2,30,31,32)/t21-,22-,29-/m1/s1
|
| Chemical Name |
[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] dihydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~195.81 mM)
H2O : ~0.67 mg/mL (~1.31 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9581 mL | 9.7907 mL | 19.5814 mL | |
| 5 mM | 0.3916 mL | 1.9581 mL | 3.9163 mL | |
| 10 mM | 0.1958 mL | 0.9791 mL | 1.9581 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02393183 | WITHDRAWN | Drug: ASTED Dietary Supplement: Selenium Other: Placebo |
Thyroid Eye Disease | Iran University of Medical Sciences | 2019-07-15 | Phase 2 Phase 3 |
| NCT05323435 | COMPLETED | Biological: Recombinant two-component COVID-19 vaccine (CHO cell) Biological: COVID-19 Vaccine (Vero Cell), Inactivated |
COVID-19 | Jiangsu Rec-Biotechnology Co., Ltd. | 2022-05-30 | Phase 2 |
| NCT03542149 | COMPLETEDWITH RESULTS | Drug: 480 mg Piperaquine phosphate Drug: 640 mg Piperaquine phosphate Drug: 200 mg OZ 439 |
Malaria | Medicines for Malaria Venture | 2018-04-23 | Phase 1 |
| NCT05084989 | COMPLETED | Biological: Part1:Recombinant two-component COVID-19 vaccine (CHO cell) Biological: Part1: Placebo Biological: Part2: Recombinant two-component COVID-19 vaccine (CHO cell) Biological: Part2: COVID-19 Vaccine, mRNA |
COVID-19 | Jiangsu Rec-Biotechnology Co., Ltd. | 2022-01-31 | Phase 2 |
| NCT05586295 | COMPLETED | Other: Placebo Other: EX plus |
Exercise Performance Fatigue |
National Taiwan Sport University | 2021-03-03 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
